Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Unsure Whether Vytorin, Zetia Can Cushion Fosamax’s Patent Loss

Executive Summary

Sales of Merck's new and inline products will drive growth in 2008 as the company turns to drugs like Januvia, Singulair, Cozaar/Hyzaar and vaccines to cushion the blow from the loss of exclusivity for Fosamax, Chief Financial Officer Peter Kellogg reported during the company's year-end financial call Jan. 30

You may also be interested in...



Vytorin/Zetia Rx Decline Prompts Schering-Plough To Issue Monthly Updates

Schering-Plough says it will soon start providing monthly updates on prescription rates for its two cholesterol drugs Vytorin (ezetimibe/simvastatin) and Zetia (ezetimibe) to help ease the minds of anxious investors

Vytorin/Zetia Rx Decline Prompts Schering-Plough To Issue Monthly Updates

Schering-Plough says it will soon start providing monthly updates on prescription rates for its two cholesterol drugs Vytorin (ezetimibe/simvastatin) and Zetia (ezetimibe) to help ease the minds of anxious investors

FDA To Review Vytorin Data: ENHANCEd Label To Follow?

FDA expects to complete a review of data from the ENHANCE study for Merck and Schering-Plough's Vytorin within nine months, Office of New Drugs Director John Jenkins announced Jan. 25

Related Content

UsernamePublicRestriction

Register

PS049267

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel